BACKGROUND: African-American children use the emergency department (ED) for asthma care more than their Caucasian counterparts. OBJECTIVE: We sought to compare ED utilization for asthma care by race, adjusting for prescriptions filled for antiinflammatory medications, type of index visit (specialist vs nonspecialist), and demographic variables. METHODS: An index asthma visit was identified for a cohort of managed care enrollees aged 4 to 11 years. Information on asthma encounters and drug claims data was evaluated during a prospective observation period of 12 months. RESULTS: African-American race was associated with one or more ED visits during the observation period (relative risk [RR] = 1.8, 95% CI = 1.3 to 2.5, p < 0.01). After adjusting for index visit type, prescriptions filled, and selected demographic variables, African-American race remained associated with post-index ED utilization (adjusted RR = 1.6, 95% CI = 1.0 to 2.4, p = 0.05). Additional findings included an inverse relationship between African-American race and antiinflammatory medications among children with nonspecialist index visits (RR = 0.5, 95% CI = 0.3 to 0.9, p = 0.02) and a positive relationship between African-American race and hospitalization after an ED visit for asthma care (RR = 10.2, 95% CI = 1.4 to 74.8, p < 0.01). CONCLUSION: African-American children were more likely to use ED asthma care even after adjusting for the type of index visit, prescriptions filled for antiinflammatory medications, and selected demographic variables. Racial differences in ED utilization for asthma care could be caused by a higher prevalence of uncontrolled or undertreated disease among African-American children not receiving specialty care.
BACKGROUND: African-American children use the emergency department (ED) for asthma care more than their Caucasian counterparts. OBJECTIVE: We sought to compare ED utilization for asthma care by race, adjusting for prescriptions filled for antiinflammatory medications, type of index visit (specialist vs nonspecialist), and demographic variables. METHODS: An index asthma visit was identified for a cohort of managed care enrollees aged 4 to 11 years. Information on asthma encounters and drug claims data was evaluated during a prospective observation period of 12 months. RESULTS: African-American race was associated with one or more ED visits during the observation period (relative risk [RR] = 1.8, 95% CI = 1.3 to 2.5, p < 0.01). After adjusting for index visit type, prescriptions filled, and selected demographic variables, African-American race remained associated with post-index ED utilization (adjusted RR = 1.6, 95% CI = 1.0 to 2.4, p = 0.05). Additional findings included an inverse relationship between African-American race and antiinflammatory medications among children with nonspecialist index visits (RR = 0.5, 95% CI = 0.3 to 0.9, p = 0.02) and a positive relationship between African-American race and hospitalization after an ED visit for asthma care (RR = 10.2, 95% CI = 1.4 to 74.8, p < 0.01). CONCLUSION: African-American children were more likely to use ED asthma care even after adjusting for the type of index visit, prescriptions filled for antiinflammatory medications, and selected demographic variables. Racial differences in ED utilization for asthma care could be caused by a higher prevalence of uncontrolled or undertreated disease among African-American children not receiving specialty care.
Authors: Doryliz Vila; Cynthia S Rand; Michael D Cabana; Amarilis Quiñones; Mirla Otero; Christina Gamache; Rafael Ramírez; Pedro García; Glorisa Canino Journal: J Asthma Date: 2010-11-01 Impact factor: 2.515
Authors: Hudin N Jackson; Caroline C Hadley; A Basit Khan; Ron Gadot; James C Bayley; Arya Shetty; Jacob Mandel; Ali Jalali; K Kelly Gallagher; Alex D Sweeney; Arif O Harmanci; Akdes S Harmanci; Tiemo Klisch; Shankar P Gopinath; Ganesh Rao; Daniel Yoshor; Akash J Patel Journal: Neurosurgery Date: 2022-01-01 Impact factor: 5.315
Authors: Djanilson Barbosa Santos; Alvaro A Cruz; Silvia de Magalhães Simões; Laura C Rodrigues; Paulo Augusto Moreira Camargos; Helena Lutescia Luna Coelho; Mauricio L Barreto Journal: Eur J Clin Pharmacol Date: 2011-06-30 Impact factor: 2.953